• linkedin
  • Increase Font
  • Sharebar

    BLC scores well against WLC in recurrent bladder tumors

    San Diego—Fluorescent blue light cystoscopy (BLC) improves 3-year recurrence-free survival (RFS) rates in patients with recurrent bladder tumors compared to white light cystoscopy (WLC), and researchers believe its use should be expanded.

    "Although BLC has been approved for index transurethral resection, its use can be extended for recurrent tumors as well," said lead author Tracy M. Downs, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, in an interview with Urology Times.

    According to Dr. Downs, "Transurethral resection of bladder tumor (TURBT) is the standard of care for the non-muscle invasive subtype. Yet there is concern over the ability of TURBT done with WLC to identify small papillary tumors and flat carcinoma in situ lesions. The recurrence rate at 5 years after TURBT tumor with WLC is reported to be as high as 70%."

    Related: Role of blue light cystoscopy to detect bladder cancer

    By contrast, "Using BLC increases detection rates of small papillary tumors by 10%-15% and carcinoma in situ lesions by 40% in meta-analyses," Dr. Downs said. "This improved cancer detection translates into improved recurrence-free survival rates. However, the effect of BLC for recurrent bladder cancer has not been well defined."

    There has been previous research in this area. At the 2017 AUA annual meeting in Boston, Siamak Daneshmand, MD, presented findings from a prospective phase III clinical trial that found blue light flexible cystoscopy with intravesical hexaminolevulinate HCL (HAL [Cysview]), significantly improved the detection of recurrent bladder tumors compared with WLC.

    Next: What the authors found

    Randy Dotinga
    Randy Dotinga is a medical writer based in San Diego, Calif.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available